Global Market Outlook on e-Consent

Although historically there has been challenges in adopting to e-Consent platform, currently there is shift in the industry. Most of the top 10 Pharma have incorporated in almost 60 percent of their trials. Buyers who were adopting at a rate of 10-11 percent last year are turning to a higher percent of adoption, close to 21-23 percent now.


Suppliers are collaborating with technology providers and amongst themselves to promote site and patient acceptance to e-Consent. Existing and new suppliers are broadening their scope of their service to align themselves to the industry shift and demand.

  • 66% of top 50 pharma are engaged or are planning to adopt to an e-Consent initiative in the near future. Most of the top 10 pharma already have an e-Consent strategy in place.
  • It is expected that, there will be a big difference when it comes to the shift in technology in the next 12 months. However, three years from now, more than 50% of the clinical trials will be adapting to e-Consent
  • Users feel the major value derived out of design and development functionalities is the use of smart devices followed by the easy content creation. This is mainly because the ability of developing a solution without vendor involvement has always been an area of worry for the stakeholders
  • Virtual care is increasingly becoming a common area of interest, as it opens a world full of possibilities for exchange of patient information.It also helps provide timely entry of any e-Informed Consent data and also for collecting subject’s consent from remote locations

Factors Impacting the Market

  • Several barriers that constrain the shift to an e-ICF mode from paper can be managed effectively, by understanding the adoption hurdles and by anticipating how the market is growing in future.
  • With the advent of virtual trials and BYOD in clinical trials, remote consent is emerging as an important topic. Patients want to use information in the comfort zone, taking the time to think and discuss with their family.